The system and process protected by the patent covers the
production of therapeutic proteins by stimulating adult stem cells
using the Company's proprietary Time-Varying Electromagnetic Field
(TVEMF) technology in a proprietary three dimensional bioreactor
system. The technology is part of Endonovo's Cytotronics™ platform, which harnesses the
bulk electrical properties of tissues and cells, namely
magnetically-induced electrical field pathways to expand and
enhance the therapeutic properties of cell therapies and to produce
human biomolecules.
Biopharmaceuticals, also known as biologics, are pharmaceutical
drug products manufactured in, extracted from, or semi-synthesized
from biological sources. These drugs differ from traditional
chemically synthesized drugs and include vaccines, hormones, blood
components, recombinant therapeutic proteins and living cells used
in cell therapies. Biologics are commonly used to stimulate the
growth of specific blood cell types, such as red and white blood
cells, and to mobilize blood stem cells from the bone marrow into
the bloodstream allowing for their collection and subsequent
transplantation into patients following chemotherapy.
Generating sales of approximately US$6 billion in 2014, and with
recent and upcoming patent expirations on a number of biologics by
the year 2020, first and next-generation G-CSF products commonly
used in the treatment of chemotherapy-induced neutropenia,
represent an attractive market for biosimilar and biosuperior
proteins, according to Competitor Analysis Series. The market for
biosimilar G-CSF is forecasted to grow at a CAGR of 20.2% from 2014
to 2019, reaching a value of $1.1 billion in 2019, according
to BCC Research.
Alan Collier, Chief Executive Officer of Endonovo, commented,
"The patent issued today represents significant and important
protection to our Cytotronics platform allowing us to move forward
with the platform's development of while addressing many of the
current drawbacks of culturing cells outside of the body to create
better cell therapies and biologics."
Mr. Collier went on to say, "Although follow-on biologics
represent a lucrative opportunity for some biotechs by potentially
costing 20-30 percent less than their brand name counterparts, we
are looking at creating next-generation biosuperior proteins that
are created using human cells rather than using recombinant-DNA
technology in E.coli and yeast systems."
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a leading developer of
bioelectronic-applications in cell therapies and non-invasive
Electroceuticals™. Endonovo's Immunotronics™ platform is dedicated
to treating patients with life-threatening inflammatory conditions,
such as acute liver injury and fulminant hepatic failure, using
proprietary non-invasive Electroceutical™ devices. The Company's
non-invasive platform is based on magnetically-induced electrical
field pathways that target inflammation and cell death.
The Company's Cytotronics™ platform harnesses the bulk
electrical properties of cells and tissues, namely
magnetically-induced electrical field pathways to expand and
enhance the therapeutic potential of cell therapies and produce
next-generation biologics.
Safe Harbor Statement
This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, trends, analysis, and other information contained
in this press release including words such as "anticipate,"
"believe," "plan," "estimate," "expect," "intend," and other
similar expressions of opinion, constitute forward-looking
statements. Any such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from any future results described within the forward-looking
statements. Risk factors that could contribute to such differences
include those matters more fully disclosed in the Company's reports
filed with the Securities and Exchange Commission. The
forward-looking information provided herein represents the
Company's estimates as of the date of the press release, and
subsequent events and developments may cause the Company's
estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied
upon as representing the Company's estimates of its future
financial performance as of any date subsequent to the date of this
press release.
Investors: Sign Up for Email Alerts on Endonovo